Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
Abstract Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized clinical trials (2 episodic trials [EVOLVE-1, EVOLVE...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2021-02-01
|
| Schriftenreihe: | The Journal of Headache and Pain |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s10194-021-01215-9 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|